{
    "body": "How many TAp73 isoforms have been identified in humans?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21946516", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22457351", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19139399", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16773194", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23271007", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21807636", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19885566", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20615966", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20926182", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22388545", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16254107", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18342333", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15059898", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12235210", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20298673", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21643019", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23470527", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11753569", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15610529", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14634023", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19861456", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12897129", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15975558", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12920125", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14676279", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15781249", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21852228", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16467208", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16322298", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19777343", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18546269", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15138575", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11830511", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12944917", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18350258", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15803372", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17626635", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22056305", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20146801", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19148480", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18477895", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19509292", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20733477", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20803057", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16964385", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20842728", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20581467", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19615968", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23159862", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16083956", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17076661", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19671150", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18039564", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18611950", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18469517", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16380414", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17029218", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17047653", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15889017", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22508983", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22484480", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20528922", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20194434", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23414597", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20807817", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11859407", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18256531", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23436675", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23362263", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23188674", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18583365", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21459846", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15752257", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16630058", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17430565", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18421303", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22740507", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17446929", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17912537", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15741235", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15467455", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16290057", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19103865", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19363520", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16980297", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17637683", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20613985"
    ], 
    "ideal_answer": [
        "The TP73 gene, due to the presence of two promoters (P1 and P2) in its 5' flanking region, encodes a fully transcriptionally active domain (TAp73) and the amino terminus deleted (\u0394Np73). TAp73 possesses pro-apoptotic properties, while deltaNp73 has anti-apoptotic functions. Alternative 3'-end splicing results in generation of at least seven TAp73 distinctive isoforms ( \u03b1, \u03b2, \u03b3, etc ).", 
        "The Trp73 gene belongs to the p53 family of transcription factors and, like the other members, is transcribed into different isoforms [1-4]. TP73 gene contains two promoters, encoding the transcriptional domain-containing (TAp73) and the amino deleted (DNp73) isoforms [5, 6]. Furthermore alternative splicing at the 3'-end (to generate a, b, g, etc isoforms) and 5'-end (to generate D2, D3 and D2-3 isoforms) results in generation of at least 14 different transcripts, with different abilities to promote or repress apoptosis [7, 8]. (PMID: 22388545)"
    ], 
    "exact_answer": [
        "seven", 
        "7"
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020033"
    ], 
    "type": "factoid", 
    "id": "5173bdb38ed59a060a000020", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 162, 
            "text": "A member of the p53 family, p73, has several isoforms and differentially regulates transcription of genes involved in the control of the cell cycle and apoptosis.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18256531", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 217, 
            "text": "The p73 gene, a homologue of the p53 tumor suppressor, is expressed as TA and \u0394N isoforms. TAp73 has similar activity as p53 and functions as a tumor suppressor whereas \u0394Np73 has both pro- and anti-survival functions.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21852228", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 103, 
            "offsetInEndSection": 316, 
            "text": "Transcription from two different promoters on the p73 gene results in generation of transcriptionally active TAp73 isoforms and dominant negative DeltaNp73 isoforms with opposing pro- and anti-apoptotic functions.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20615966", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 78, 
            "offsetInEndSection": 426, 
            "text": "We have evaluated the differential expression and subcellular localization of the functionally distinct apoptotic (TA) and anti-apoptotic (DeltaN) isoforms of p73 in non-small cell lung cancer (NSCLC), their possible association with p53 expression and determined the methylation status of the two p73 gene promoters (P1 and P2) in this tumor type.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19148480", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 403, 
            "text": "The role of various p73 isoforms in tumorigenesis has been controversial. However, as we have recently shown, the generation of TAp73-deficient (TAp73(-/-)) mice reveals that TAp73 isoforms exert tumor-suppressive functions, indicating an emerging role for Trp-73 in the maintenance of genomic stability. Unlike mice lacking all p73 isoforms, TAp73(-/-) mice show a high incidence of spontaneous tumors.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19139399", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 150, 
            "offsetInEndSection": 445, 
            "text": "Alternative promoters and N-terminal splicing result in the transcription and processing of either full-length (TA) or N-terminally truncated (deltaN) p73 isoforms. TAp73 possesses pro-apoptotic functions, while deltaNp73 has anti-apoptotic properties via functional inhibition of TAp73 and p53.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16980297", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 132, 
            "text": "The p73 gene is able to encode transcriptionaly active TAp73, as well as a dominant-negatively acting DeltaNp73 transcript isoforms.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15138575", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 143, 
            "offsetInEndSection": 333, 
            "text": "Since some mutant p53 proteins and \u0394Np73 isoforms form heterocomplexes with TAp73, we asked whether p53 isoforms can do the same and potentially act as dominant-negative inhibitors of TAp73.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23188674", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 71, 
            "text": "p73, a p53 family tumor suppressor, is expressed as TA and \u0394N isoforms.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22508983", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 107, 
            "text": "p73 is expressed as TA and \u0394N isoforms, both of which are implicated in tumor suppression and/or promotion.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22457351", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 881, 
            "offsetInEndSection": 971, 
            "text": "We found that TAp73 isoforms are down regulated in oocytes from women older than 38 years.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21946516", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 182, 
            "text": "p73 possesses an extrinsic P1 promoter and an intrinsic P2 promoter controlling the expression of the pro-apoptotic TAp73 isoforms and the anti-apoptotic \u0394\u039dp73 isoforms respectively.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20926182", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 870, 
            "offsetInEndSection": 1150, 
            "text": "BRCA1-deficient ovarian carcinoma cells exhibit hypermethylation within a p73 regulatory region, which includes the binding site for the p73 transcriptional repressor ZEB1, leading to the abrogation of ZEB1 binding and increased expression of transactivating p73 isoforms (TAp73).", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20807817", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 359, 
            "offsetInEndSection": 540, 
            "text": "In this study, we investigated the expression and subcellular distribution of two N-terminal isoforms, TAp73 and \u0394Np73, in medulloblastoma cells using immunofluorescence microscopy.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20803057", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 409, 
            "offsetInEndSection": 600, 
            "text": "Proteasomal degradation of p73 is mediated by polyubiquitination-dependent and -independent processes both of which appear, thus far, to lack selectivity for the TAp73 and DeltaNp73 isoforms.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20615966", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 218, 
            "offsetInEndSection": 406, 
            "text": "In general, TAp73 isoforms show proapoptotic activities, whereas members of the N-terminally truncated (\u0394N) p73 subfamily that lack the transactivation domain show antiapoptotic functions.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20581467", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 135, 
            "text": "The p73 gene possesses an extrinsic P1 promoter and an intrinsic P2 promoter, resulting in TAp73 and DeltaNup73 isoforms, respectively.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20528922", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 145, 
            "text": "Mice with a complete deficiency of p73 have severe neurological and immunological defects due to the absence of all TAp73 and DeltaNp73 isoforms.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20194434", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 713, 
            "offsetInEndSection": 822, 
            "text": "Moreover, we also found that subcellular location of p73 isoforms changes with the culture density increases.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19885566", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1133, 
            "offsetInEndSection": 1271, 
            "text": "Moreover, ectopic expression of DeltaNp73alpha (but not other p73 isoforms) increased alphaB-crystallin mRNA levels in the absence of p53.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19777343", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 329, 
            "offsetInEndSection": 437, 
            "text": "Like wt p53, TAp63 and TAp73 isoforms transactivate target genes that activate apoptosis signaling pathways.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19615968", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 130, 
            "text": "The TP73 gene gives rise to transactivation domain-p73 isoforms (TAp73) as well as DeltaNp73 variants with a truncated N terminus.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19509292", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 225, 
            "offsetInEndSection": 344, 
            "text": "In contrast, antiapoptotic DeltaNp73 isoforms lack the TA domain and are dominant-negative inhibitors of p53 and TAp73.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19363520", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 125, 
            "offsetInEndSection": 336, 
            "text": "The isoforms TAp63 and TAp73 transactivate p53 target genes and induce apoptosis, whereas the isoforms DeltaNp63 and DeltaNp73 lack transactivation and might have dominant-negative effects in p53 family members.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19103865", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 347, 
            "offsetInEndSection": 602, 
            "text": "The expression of all 5 N-terminal isoforms (TAp73, DeltaNp73, DeltaN'p73, Ex2p73 and Ex2/3p73) was measured by real-time RT-PCR and p53 status was analyzed by immunohistochemistry. TAp73, DeltaNp73 and DeltaN'p73 were significantly upregulated in tumors.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16964385", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 552, 
            "offsetInEndSection": 734, 
            "text": "Consequently, different p73 isoforms can be degraded by calpains, i.e., both N-terminal isoforms (TAp73 and DeltaNp73) as well as the C-terminal isoforms (alpha, beta, gamma, delta).", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15975558", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 218, 
            "offsetInEndSection": 343, 
            "text": "Variants lacking the TA domain (DeltaN isoforms) are induced by TAp73 and by p53, and inhibit their transcriptional activity.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15781249", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 429, 
            "offsetInEndSection": 675, 
            "text": "Indeed, tazarotene modulates the expression of the p73 gene in immortalized keratinocyte cell lines by inducing the pro-apoptotic and anti-proliferative TAp73 isoforms and by repressing the anti-apoptotic and pro-proliferative DeltaNp73 isoforms.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15610529", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 211, 
            "text": "p73, the first p53 gene homologue, encodes an array of p73 proteins including p73 alpha full-length (TAp73 alpha) and amino-truncated isoforms (Delta Np73 alpha), two proteins with opposite biological functions.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/14676279", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 329, 
            "offsetInEndSection": 567, 
            "text": "We further showed that DeltaNp73 is a potent transdominant inhibitor of wild-type p53 and TAp73 in cultured human tumor cells by efficiently counteracting their target gene transactivations, apoptosis, and growth suppression functions (A.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12897129", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 216, 
            "offsetInEndSection": 408, 
            "text": "In developing sympathetic neurons of mice, p73 is predominantly expressed as a truncated anti-apoptotic isoform (DeltaNp73), which antagonizes both p53 and the full-length p73 protein (TAp73).", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/11859407", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1358, 
            "offsetInEndSection": 1561, 
            "text": "Interestingly, expression of the Delta Np73 is strongly up-regulated by the TA isoforms and by p53, thus creating a feedback loop that tightly regulates the function of TAp73 and more importantly of p53.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/11753569", 
            "endSection": "sections.0"
        }
    ]
}